ALKS - Alkermes plc
45.04 0.00 (0.00%)
After hours: 4:33PM EDT
| Previous Close | 45.28 |
| Open | 45.53 |
| Bid | 44.95 x 300 |
| Ask | 45.70 x 500 |
| Day's Range | 44.83 - 45.64 |
| 52 Week Range | 39.54 - 71.22 |
| Volume | 420,040 |
| Avg. Volume | 745,163 |
| Market Cap | 6.983B |
| Beta | 2.57 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.99 |
| Earnings Date | Jul 26, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 53.50 |
- PR Newswire•yesterday
Alkermes to Host Conference Call to Discuss Second Quarter 2018 Financial Results
DUBLIN , July 19, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:30 a.m. ET ( 1:30 p.m. BST ) on Thursday, July 26, 2018 , to discuss the company's ...
Markit•yesterdaySee what the IHS Markit Score report has to say about Alkermes PLC.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
Market Realist•14 days agoWhy Wall Street Analysts Are Mostly Positive on Alkermes
Today, Alkermes (ALKS) is trading at a stock price of $42.29, which represents ~2.62% growth from its prior close of $41.21 on July 5.
- Benzinga•15 days ago
A Look At Biotech In 2018 And The Biggest Catalysts Coming Up In The Second Half Of The Year
Biotech stocks carved out modest gains in the first half of 2018 and outperformed the broader market, although their gains paled before those of the tech-weighted Nasdaq Composite Index. From the fundamental ...
- Zacks•17 days ago
Alkermes' Aristada Initio Approved by FDA for Schizophrenia
FDA approves Alkermes' (ALKS) Aristada Initio (aripiprazole lauroxil) for the treatment of schizophrenia in adults.
- Benzinga•18 days ago
Benzinga Pro's 5 Stocks To Watch Today
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Alkermes Plc (NASDAQ: ALKS ) stock was trading higher ...
- PR Newswire•19 days ago
FDA Approves ARISTADA INITIO™ for the Initiation of ARISTADA® for Schizophrenia
DUBLIN, July 2, 2018 /PRNewswire/ -- Alkermes plc (ALKS) today announced that the U.S. Food and Drug Administration (FDA) has approved ARISTADA INITIO™ (aripiprazole lauroxil) for the initiation of ARISTADA® (aripiprazole lauroxil), a long-acting injectable atypical antipsychotic for the treatment of schizophrenia in adults. For the first time, ARISTADA INITIO, in combination with a single 30 mg dose of oral aripiprazole, provides physicians with an alternative regimen to initiate patients onto any dose of ARISTADA on day one. ARISTADA INITIO is expected to be available in mid-July.
- Benzinga•26 days ago
The Week Ahead In Biotech: Conferences, Clinical Trials And IPOs
Biotech stocks saw some upward momentum last week. The defensive nature of biotech stocks drove investors into the space amid a rise in risk aversion following the ongoing U.S.-China trade war. The week ...
- Motley Fool•29 days ago
Why Alkermes Tumbled 15% Today
A downgrade by a big investment bank took a toll on the company's shares today.
- Motley Fool•29 days ago
Why Stamps.com, iQiyi, and Alkermes Slumped Today
Find out which of these companies could suffer from a government move.
- MarketWatch•29 days ago
Drugs from Heron Therapeutics and two other biotech companies can boost your investment returns by reducing opioid abuse
Heron Therapeutics, Cara Therapeutics and Alkermes are discovering novel replacements for dangerous opioidsAbout 2.1 million people in the U.S. suffer from opioid abuse. While investors are focused on trade wars as a potential threat to their wealth, drug abuse may be the bigger risk. Fortunately, three biotech companies are coming to the rescue, which makes them good investments.
- ACCESSWIRE•last month
Breakfast Technical Briefing on Alkermes and Three Other Additional Biotech Stocks
Research coverage has been initiated by WallStEquities.com on Aimmune Therapeutics Inc. (NASDAQ: AIMT), Alkermes PLC (NASDAQ: ALKS), Aratana Therapeutics Inc. (NASDAQ: PETX), and ARCA biopharma Inc. (NASDAQ: ABIO). The majority of Biotech companies research and develop products for the healthcare market.
Markit•last monthSee what the IHS Markit Score report has to say about Alkermes PLC.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
- ACCESSWIRE•last month
Wired News – Alkermes Gets License Payment from Biogen Following Review of Preliminary Gastrointestinal Tolerability Data of BIIB098 for Multiple Sclerosis Treatment
LONDON, UK / ACCESSWIRE / June 08, 2018 / If you want access to our free research report on Alkermes PLC (NASDAQ: ALKS), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ALKS as the Company's latest news hit the wire. On June 06, 2018, the Company announced that it has received a $50 million payment from Biogen, Inc. (NASDAQ: BIIB), following the latter's review of preliminary gastrointestinal tolerability data from the ongoing clinical development program for BIIB098 (formerly known as ALKS 8700), which is an oral fumarate in Phase-3 development for the treatment of relapsing forms of multiple sclerosis (MS).
- PR Newswire•last month
Alkermes to Present at Goldman Sachs 39th Annual Global Healthcare Conference
DUBLIN , June 6, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its Chief Executive Officer, Richard Pops , will participate in a fireside chat at the Goldman Sachs 39 th Annual ...
- Benzinga•last month
Benzinga Pro's 5 Stocks To Watch Today
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Tesla Inc (NASDAQ: TSLA ) stock was trading higher ...
- Simply Wall St.•last month
Alkermes plc (NASDAQ:ALKS): Is Breakeven Near?
Alkermes plc’s (NASDAQ:ALKS): Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland,Read More...
- PR Newswire•last month
Alkermes Receives $50 Million Payment From Biogen Following Review of Preliminary Gastrointestinal Tolerability Data From the Ongoing BIIB098 Clinical Development Program
DUBLIN, June 6, 2018 /PRNewswire/ -- Alkermes plc (ALKS) today announced it has received a $50 million payment from Biogen. This payment follows Biogen's review of preliminary gastrointestinal tolerability data from the ongoing clinical development program for BIIB098 (diroximel fumarate). BIIB098 (formerly ALKS 8700) is a novel, oral fumarate in phase 3 development for the treatment of relapsing forms of multiple sclerosis (MS).
- GlobeNewswire•2 months ago
Detailed Research: Economic Perspectives on Bank of Nova Scotia, Eaton Corporation, Canadian National Railway, MakeMyTrip, Altisource Portfolio Solutions S.A., and Alkermes plc — What Drives Growth in Today's Competitive Landscape
NEW YORK, June 04, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Bank ...
- PR Newswire•2 months ago
Alkermes' Corporate Presentation to be Webcast at the Jefferies 2018 Healthcare Conference
DUBLIN , May 29, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its corporate presentation will be webcast live at the Jefferies 2018 Healthcare Conference on Tuesday, June 5, 2018 ...
- PR Newswire•2 months ago
Alkermes to Present Data on Depression and Schizophrenia Portfolios at Upcoming American Society of Clinical Psychopharmacology Annual Meeting
-- Long-Term Safety and Clinical Evaluation of Abuse Potential of ALKS 5461 to be Highlighted -- DUBLIN , May 23, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that new clinical data ...
- PR Newswire•2 months ago
Alkermes' Corporate Presentation to be Webcast at the UBS Global Healthcare Conference
DUBLIN , May 14, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its corporate presentation will be webcast live at the UBS Global Healthcare Conference on Monday, May 21, 2018 at ...
- Zacks•2 months ago
The Zacks Analyst Blog Highlights: Seagate, Grafton, Ingersoll-Rand and Alkermes
The Zacks Analyst Blog Highlights: Seagate, Grafton, Ingersoll-Rand and Alkermes
- PR Newswire•2 months ago
Alkermes' Corporate Presentation to be Webcast at the Bank of America Merrill Lynch Health Care Conference
DUBLIN , May 10, 2018 /PRNewswire/ -- Alkermes plc (NASDAQ: ALKS) announced today that its corporate presentation will be webcast live at the Bank of America Merrill Lynch Health Care Conference on Wednesday, ...
